NCT01217931 2026-01-30Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START TrialM.D. Anderson Cancer CenterPhase 2 Active not recruiting180 enrolled
NCT04195750 2025-04-29A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)Merck Sharp & Dohme LLCPhase 3 Active not recruiting755 enrolled 28 charts 2 FDA